Seelos Financial Statements From 2010 to 2024
| SEEL Stock | USD 0.39 0.11 22.00% |
Check Seelos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Seelos Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Seelos financial statements analysis is a perfect complement when working with Seelos Therapeutics Valuation or Volatility modules.
Seelos |
Seelos Therapeutics OTC Stock Return On Equity Analysis
Seelos Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Seelos Therapeutics Return On Equity | -5.84 |
Most of Seelos Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seelos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Seelos Therapeutics has a Return On Equity of -5.842. This is 75.63% lower than that of the Pharmaceuticals sector and 83.98% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Seelos Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Seelos Therapeutics's current stock value. Our valuation model uses many indicators to compare Seelos Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Seelos Therapeutics competition to find correlations between indicators driving Seelos Therapeutics's intrinsic value. More Info.Seelos Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Seelos Therapeutics' earnings, one of the primary drivers of an investment's value.About Seelos Therapeutics Financial Statements
Seelos Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Seelos OTC Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York. Seelos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Seelos OTC Stock
Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.